EPM2A (EPM2A Glial Protein, also known as laforin) is a critical gene located on chromosome 6q24 that encodes a unique dual-specificity phosphatase essential for glycogen metabolism. The gene is catalogued as NCBI Gene ID 79583 and OMIM 607051. Pathogenic variants in EPM2A cause Lafora disease (LD), a devastating progressive myoclonic epilepsy characterized by the accumulation of abnormal glycogen deposits (Lafora bodies) in neurons and other tissues[@turnbull2024][@ganesan2023].
The protein encoded by EPM2A is EPM2A Protein (laforin), which represents a unique class of phosphatases containing both a catalytic dual-specificity phosphatase domain and a carbohydrate-binding module (CBM) that targets the enzyme specifically to glycogen particles[@garcagimeno2013]. This dual-domain architecture makes laforin the only known phosphatase that directly interacts with and dephosphorylates glycogen, positioning it as a master regulator of glycogen metabolism in the brain.
| EPM2A Gene |
|---|
| Gene Symbol | EPM2A |
| Full Name | EPM2A Glial Protein (Laforin) |
| Chromosome | 6q24 |
| NCBI Gene ID | [79583](https://www.ncbi.nlm.nih.gov/gene/79583) |
| OMIM | [607051](https://omim.org/entry/607051) |
| Ensembl ID | [ENSG00000129680](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000129680) |
| UniProt ID | [Q9U6X3](https://www.uniprot.org/uniprot/Q9U6X3) |
| Protein Length | 331 amino acids |
| Molecular Weight | ~37 kDa |
| Associated Diseases | [Lafora Disease](/diseases/lafora-disease) |
¶ Gene Structure and Evolution
The EPM2A gene spans approximately 4.5 kb on the long arm of chromosome 6 (6q24) and consists of a single exon encoding the 331-amino acid laforin protein. The gene is evolutionarily conserved, with orthologs identified in mammals, zebrafish (Danio rerio), Drosophila melanogaster, and yeast (Saccharomyces cerevisiae). The conservation of laforin across eukaryotes reflects its fundamental role in glycogen metabolism[@minassian2012].
¶ Protein Domain Architecture
Laforin possesses a unique dual-domain structure that distinguishes it from other dual-specificity phosphatases:
-
N-terminal Carbohydrate-Binding Module (CBM): Residues 1-125 comprise a starch-binding domain that targets laforin specifically to glycogen particles. This domain contains a hydrophobic pocket that recognizes the glucose polymer structure of glycogen[@worby2006].
-
C-terminal Dual-Specificity Phosphatase (DSP) Domain: Residues 150-331 contain the catalytic phosphatase domain with the signature HCX5R motif. This domain dephosphorylates both phosphotyrosine and phosphoserine/threonine residues on target proteins and can also dephosphorylate glycogen itself[@garcagimeno2013].
The presence of a CBM in a phosphatase is extremely rare, making laforin a unique enzyme. This adaptation likely evolved to allow direct regulation of glycogen metabolism in cells, particularly neurons where glycogen serves as a critical energy reserve.
Laforin plays multiple essential roles in glycogen homeostasis:
Dephosphorylation of Glycogen: Laforin removes phosphate groups from glycogen, maintaining proper glycogen structure. Hyperphosphorylated glycogen has fewer branches and forms insoluble precipitates (polyglucosan) that accumulate as Lafora bodies[@turnbull2012].
Interaction with Malin: Laforin forms a functional complex with malin (encoded by EPM2B/NHLRC1), an E3 ubiquitin ligase. This laforin-malin complex coordinately regulates glycogen metabolism through:
- Laforin dephosphorylates glycogen and glycogen-associated proteins
- Malin ubiquitinates and targets proteins for degradation
- Together, they maintain glycogen quality control[@singh2013]
Regulation of Glycogen Branching Enzyme (GBE): The laforin-malin complex regulates the activity and stability of glycogen branching enzyme (GBE/GBE1), which is essential for creating properly branched glycogen. Loss of laforin function leads to hyperphosphorylated, poorly branched glycogen[@pardo2020].
Laforin participates in cellular stress response pathways:
Endoplasmic Reticulum (ER) Stress: Laforin localizes to the ER and participates in ER stress response pathways. Loss of laforin leads to increased ER stress and activation of the unfolded protein response (UPR)[@ortolano2014].
Autophagy Regulation: Laforin interacts with autophagy machinery and regulates autophagic flux. Impaired autophagy contributes to Lafora body accumulation and neurodegeneration in LD[@jimenez2019].
Mitochondrial Function: Recent evidence suggests laforin may influence mitochondrial function and protect against oxidative stress in neurons[@valenti2020].
Lafora disease (LD) is an autosomal recessive progressive neurodegenerative disorder caused by pathogenic variants in EPM2A (approximately 50-60% of cases) or EPM2B/NHLRC1 (approximately 20-30% of cases). The disease typically presents in adolescence with myoclonic seizures and rapidly progresses to severe cognitive decline, motor impairment, and premature death within 10-15 years of onset[@schneider2016].
The pathogenic mechanism involves:
- Loss of Laforin Phosphatase Activity: Pathogenic variants impair laforin's ability to dephosphorylate glycogen
- Glycogen Hyperphosphorylation: Abnormal glycogen becomes hyperphosphorylated and poorly branched
- Polyglucosan Formation: Hyperphosphorylated glycogen forms insoluble polyglucosan precipitates
- Lafora Body Accumulation: Polyglucosan accumulates as Lafora bodies in neurons, muscle, liver, and other tissues
- Neurodegeneration: Lafora bodies trigger ER stress, autophagy impairment, neuroinflammation, and neuronal death[@sanchezelexpuru2024]
Over 40 pathogenic variants in EPM2A have been identified in patients with Lafora disease[@shah2019]:
- D146N: Most common mutation, affects catalytic activity
- G240S: Impairs carbohydrate-binding domain function
- R241C: Disrupts protein stability
- P301A: Affects phosphatase domain
- H321Y: Reduces catalytic activity
Genotype-phenotype correlations suggest that certain variants (such as nonsense mutations) are associated with earlier onset and more severe disease, while missense mutations may have slightly milder phenotypes.
The primary pathological hallmark of LD is the accumulation of Lafora bodies—intracytoplasmic inclusions composed of abnormal glycogen (polyglucosan). These inclusions:
- Disrupt neuronal morphology and function
- Impair cellular transport and organelle function
- Trigger inflammatory responses
- Progressively accumulate with disease duration
¶ ER Stress and Unfolded Protein Response
Loss of laforin function leads to chronic ER stress:
- Accumulation of misfolded proteins and abnormal glycogen in the ER lumen
- Activation of PERK, IRE1, and ATF6 signaling branches
- Pro-apoptotic signaling through CHOP
- Contribution to neuronal dysfunction and death[@ortolano2014]
Laforin deficiency impairs autophagic flux:
- Reduced clearance of polyglucosan and protein aggregates
- Accumulation of damaged organelles
- Activation of inflammatory responses
- Contribution to neurodegeneration[@jimenez2019]
Progressive neuroinflammation is a key feature of LD pathogenesis:
- Microglial activation in affected brain regions
- Astrocyte reactivity
- Elevated pro-inflammatory cytokines
- Contributes to seizure generation and cognitive decline[@lopez2018]
Mitochondrial abnormalities contribute to neuronal loss:
- Reduced mitochondrial respiration
- Increased reactive oxygen species (ROS)
- Impaired calcium buffering
- Activation of apoptotic pathways[@valenti2020]
Seizures are the presenting symptom in most LD patients:
- Myoclonic seizures: Characteristic, often very frequent and disabling
- Tonic-clonic seizures: Generalized seizures common
- Atonic seizures: Drop attacks
- Absence seizures: Brief lapses of awareness
- Status epilepticus: May occur, particularly in later stages[@crino2019]
Progressive cognitive impairment follows seizure onset:
- Memory deficits, particularly episodic and working memory
- Executive dysfunction
- Language deterioration
- Behavioral changes including depression, anxiety, and psychosis
- Progressive dementia within years of onset
Progressive motor impairment develops over time:
- Ataxia and gait disturbance
- Dysarthria (speech difficulties)
- Dysphagia (swallowing difficulties)
- Spasticity and increased muscle tone
Psychiatric manifestations include:
- Depression and anxiety
- Visual hallucinations
- Personality changes
¶ Diagnosis and Testing
Molecular genetic testing provides definitive diagnosis:
- Sequencing: Analysis of EPM2A and EPM2B genes
- Panel testing: Multi-gene panels for progressive myoclonic epilepsy
- Carrier testing: For at-risk family members
¶ Biomarkers and Diagnostic Aids
- Lafora bodies in skin biopsy: Detection in eccrine gland cells
- Glycogen accumulation: Measured in muscle or skin fibroblasts
- Neurofilament light chain: Marker of axonal injury
- MRI: Cerebral atrophy, white matter changes, cerebellar atrophy[@iannizzotto2014]
No disease-modifying therapy exists. Management focuses on:
Antiseizure Medications: Valproic acid, clonazepam, levetiracetam, perampanel, zonosamide—often in combination
Supportive Care: Physical therapy, occupational therapy, speech therapy, nutritional support, psychiatric care
Multiple approaches under investigation:
- AAV vectors: Deliver functional EPM2A to the central nervous system
- Gene editing: CRISPR-based approaches to correct pathogenic variants
- Antisense oligonucleotides: Target specific mutations[@gedela2021][@agrawal2020]
- Metformin: May reduce glycogen accumulation
- Dichloroacetate: Targets metabolic abnormalities
- SGLT2 inhibitors: Being explored for glycogen reduction
- Rapamycin/mTOR inhibition: May enhance autophagy
- Molecular chaperones: Help fold abnormal proteins
- Autophagy-inducing compounds: Clear Lafora bodies[@ahmadi2020]
¶ Expression and Regulation
EPM2A is highly expressed in the brain:
- Cerebral cortex: Particularly Layer V pyramidal neurons
- Hippocampus: CA1-CA3 regions and dentate gyrus
- Cerebellum: Purkinje cells and granule cells
- Brainstem: Various nuclei
Expression data is available from the Allen Human Brain Atlas.
EPM2A expression is regulated by:
- Transcription factors: CREB and other neuron-specific regulators
- Cellular stress: Upregulated under ER stress conditions
- Developmental stage: Higher expression in developing brain
Several animal models have been developed:
Mouse Models:
- Epm2a knockout mice
- Transgenic mice expressing mutant Epm2a
- Conditional knockout models
Zebrafish Models:
- morpholino knockdown models
- CRISPR knock-in models
- Useful for drug screening[@vazquezmanrique2019]
Drosophila Models:
- dEpm2a RNAi and knockout lines
- Rapid genetic screening capabilities
These models have been instrumental in understanding pathogenesis and testing therapeutic approaches.
- Turnbull J, et al., EPM2A mutations in Lafora Disease. Brain, 2024 (2024)
- Ganesan V, et al., Laforin function and glycogen metabolism. J Neurochem, 2023 (2023)
- Sanchez-Elexpuru B, et al., EPM2A and glycogen hyperphosphorylation in Lafora Disease. Acta Neuropathol, 2024 (2024)
- Minassian BA, et al., Laforin disease and the laforin glycogen phosphatase. Mol Genet Metab, 2012 (2012)
- García-Gimeno MA, et al., Laforin: a unique dual-specificity phosphatase. Cell Signal, 2013 (2013)
- Turnbull J, et al., Glycogen hyperphosphorylation underlies Lafora disease. J Clin Invest, 2012 (2012)
- Singh PK, et al., The laforin-malin complex regulates glycogen metabolism. Neurobiol Dis, 2013 (2013)
- Worby CA, et al., Laforin: a atypical dual specificity phosphatase. J Biol Chem, 2006 (2006)
- Ganesh S, et al., Laforin interacts with EPM2A/IPP and regulates glycogen metabolism. J Biol Chem, 2006 (2006)
- Roach PJ, et al., Glycogen metabolism and laforin in Lafora disease. J Clin Invest, 2003 (2003)
- Shah M, et al., EPM2A variants and phenotype in Lafora disease. Neurology, 2019 (2019)
- Jiménez R, et al., Autophagy in Lafora disease pathogenesis. Autophagy, 2019 (2019)
- López-González I, et al., Neuroinflammation in Lafora disease. Acta Neuropathol Commun, 2018 (2018)
- Martínez FR, et al., Mouse models of Lafora disease. Neurobiol Dis, 2017 (2017)
- Gedela S, et al., Gene therapy for Lafora disease. Mol Ther Methods Clin Dev, 2021 (2021)
- Crino PB, et al., Epilepsy in Lafora disease. Epilepsia, 2019 (2019)
- Ahmadi S, et al., Metabolic therapies in Lafora disease. J Inherit Metab Dis, 2020 (2020)
- Schneider A, et al., Clinical management of Lafora disease. Lancet Neurol, 2016 (2016)
- Pardo B, et al., Glycogen branching enzyme and laforin interaction. J Biol Chem, 2020 (2020)
- Fernández JM, et al., PTG and glycogen metabolism in Lafora disease. Cell Mol Neurobiol, 2021 (2021)
- Vázquez-Manrique RP, et al., Zebrafish models of Lafora disease. Dis Model Mech, 2019 (2019)
- Iannizzotto F, et al., Skin biopsy for Lafora disease diagnosis. Neurology, 2014 (2014)
- Valenti L, et al., Mitochondrial dysfunction in Lafora disease. Free Radoc Biol Med, 2020 (2020)
- Ortolano S, et al., ER stress in Lafora disease. Cell Death Dis, 2014 (2014)
- Agrawal A, et al., CRISPR-Cas9 gene editing for Lafora disease. Mol Ther Nucleic Acids, 2020 (2020)
Page expanded as part of NeuroWiki Quest: Evidence Depth initiative - batch 41